Insider David Scott Moore Buys CRVS Shares
David Scott Moore purchased 15,000 shares of CRVS on June 11.
Key Points
- David Scott Moore bought 15,000 shares of CRVS on June 11, with the stock trading at $11.93.
- CRVS shares have been actively traded by institutional investors, with BlackRock adding over 1.1 million shares.
- Analysts maintain a positive outlook on CRVS, with Goldman Sachs setting a $40 price target.
On June 11, 2026, insider David Scott Moore purchased 15,000 shares of CRVS. This transaction was not part of a pre-planned trading program, and the shares were acquired at no cost. The market valued CRVS stock at $11.93 on the same day.
Insider Buying and Selling at Corvus Pharmaceuticals, Inc.
Several insiders, including David Scott Moore, were active on June 11, 2026. Moore acquired 15,000 shares, while Peter Thompson, Richard Van Den Broek, Linda Grais, and Ian Clark each bought the same number of shares. These transactions were not planned in advance, and each insider acquired their shares at no cost.
Other Institutional Activity in CRVS
Institutional investors have shown interest in CRVS. BlackRock, Inc. increased its holdings by over 1.1 million shares, bringing its total to 6,160,422 shares valued at approximately $90.1 million. State Street Corp also boosted its position by 777,769 shares, resulting in 3,565,992 shares worth about $52.2 million. Meanwhile, Price T Rowe Associates dramatically increased its stake by nearly 2.9 million shares, totaling 2,917,300 shares valued at $42.7 million.
Analysts Set New Price Targets
Analysts maintain a favorable view of CRVS, with several firms reiterating or initiating positive ratings. On April 17, 2026, Goldman Sachs initiated coverage with a 'buy' rating and a $40 price target. Oppenheimer reiterated its 'buy' rating with a $33 target on March 13, 2026. Jefferies maintained its 'buy' stance with a $42 target on January 22, 2026. The consensus among analysts is a 'buy', reflecting a positive outlook for the stock.
Bottom Line
The recent insider purchases by David Scott Moore and others suggest confidence in CRVS's prospects. Institutional interest, as evidenced by BlackRock's significant share increase, further underscores this sentiment. Analysts are optimistic, with several firms setting high price targets. As always, it's important to remember that insider and institutional activities are historical data and may not indicate future performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.